BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 2601685)

  • 1. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of receptors for gastrin and CCK on gastric smooth muscle cells.
    Menozzi D; Gardner JD; Jensen RT; Maton PN
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G73-9. PubMed ID: 2473654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.
    Lin CW; Miller T
    J Pharmacol Exp Ther; 1985 Mar; 232(3):775-80. PubMed ID: 2983069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
    Zhou W; Povoski SP; Bell RH
    J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
    Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization.
    Zhou W; Povoski SP; Longnecker DS; Bell RH
    Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
    Cancer Res; 1993 Sep; 53(17):3925-9. PubMed ID: 8358719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both CCK-A and CCK-B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands.
    Lin CW; Bianchi BR; Miller TR; Witte DG; Wolfram CA
    Am J Physiol; 1992 Jun; 262(6 Pt 1):G1113-20. PubMed ID: 1616041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS; Lotti VJ; Chen TB; Kunkel KA
    Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SNF 9007, a novel cholecystokinin/opoid ligand in mouse ileum in vitro: evidence for involvement of cholecystokininA and cholecystokininB receptors in regulation of ion transport.
    Rao RK; Levenson S; Fang SN; Hruby VJ; Yamamura HI; Porreca F
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1003-9. PubMed ID: 8113956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCKA and CCKB receptors are expressed in small cell lung cancer lines and mediate Ca2+ mobilization and clonal growth.
    Sethi T; Herget T; Wu SV; Walsh JH; Rozengurt E
    Cancer Res; 1993 Nov; 53(21):5208-13. PubMed ID: 8221657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.